Famotidine (famotidine) lyophilisate for solution for injections 20 mg. №5 vial


Manufacturer: Ukraine

Benign stomach ulcer. Peptic ulcer of the duodenum (treatment and prevention of relapses). Hypersecretory conditions such as Zollinger-Ellison syndrome. Treatment of gastroesophageal reflux disease (reflux-esophagitis). To prevent the development of symptoms and erosions or ulceration associated with gastroesophageal reflux disease.



Famotidine Storage
active substance: famotidine;

1 vial contains famotidine 20 mg;

Excipients: aspartic acid, mannitol (E 421).

Dosage form
Lyophilisate for solution for injection.

Main physical and chemical properties: lyophilized porous mass of white or almost white color.

Pharmacotherapeutic group
Remedies for peptic ulcer and gastroesophageal reflux disease. H2-receptor antagonists. Famotidine. ATX code A02B A03.

Pharmacological properties


Is a potent competitive inhibitor of H2-histamine receptors. The main clinically significant pharmacological action of famotidine is the inhibition of gastric secretion. Famotidine reduces both acid concentration and gastric secretion, while pepsin production remains proportional to the amount of gastric juice secreted.

In healthy volunteers and patients with hypersecretion, famotidine inhibits basal and nocturnal gastric secretion, as well as secretion stimulated by pentagastrin, betazole, caffeine, insulin, and the physiological vagus reflex.

The duration of inhibition of secretion at doses of 20 mg and 40 mg is from 10 to 12 hours.

Single oral administration of doses of 20 mg and 40 mg in the evening provides inhibition of basal and nocturnal acid secretion.

Famotidine has virtually no effect on gastrin levels on an empty stomach or after a meal.

Does not affect gastric emptying, exocrine function of the pancreas, blood flow in the liver and portal system.

Does not affect the liver cytochrome P450 enzyme system.

No antiandrogenic effect of the drug was observed. Serum hormone levels did not change after treatment with famotidine.


The kinetics of famotidine are linear.

Distribution. Plasma protein binding is relatively weak at 15-20%.

The half-life is 2.3-3.5 hours. In patients with severe renal insufficiency, the half-life of famotidine may exceed 20 hours.

Metabolism. The drug is metabolized in the liver. The only metabolite found in humans is sulfoxide.

Breeding. Is excreted by the kidneys (65-70%), 30-35% of the drug is metabolized. Renal clearance is 250-450 ml / min, indicating some degree of tubular secretion. 25-30% of the oral dose and 65-70% of the intravenous dose are excreted unchanged in the urine. A small amount of the administered dose can be excreted in the form of sulfoxide.

Benign gastric ulcer.

Peptic ulcer of the duodenum.

Conditions of hypersecretion, such as Zollinger-Ellison syndrome.

Gastroesophageal reflux disease.

Prevention of aspiration of acidic gastric contents (Mendelssohn’s syndrome) during general anesthesia.

Hypersensitivity to any component of the drug and to other antagonists

H2-histamine receptors.

Children’s age; period of pregnancy or breastfeeding (due to lack of necessary clinical experience).